Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.62 |
| ▸ | IGF1R | P08069 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7301958 | 0.94 | ADORA1 (0.66) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL7303349 | 0.94 | ADORA1 (0.65) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL7301517 | 0.93 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL7292830 | 0.93 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL7303029 | 0.93 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL7301555 | 0.93 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL7292724 | 0.93 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL7300326 | 0.93 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL7290142 | 0.93 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL7301948 | 0.90 | ADORA1 (0.59) | ADORA1IGF1RMAPK1MAPK14MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1429775-A4 | METHODS OF TREATING PULMONARY DISEASE | BIOGEN IDEC INC (US) | 2007-04-11 | — | — | EP | claimed |
| US-20040259889-A1 | Methods of treating pulmonary disease | BIOGEN IDEC MA INC. | 2004-12-23 | — | — | US | claimed |
| EP-1429775-A1 | METHODS OF TREATING PULMONARY DISEASE | Biogen Idec MA Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2003022284-A1 | METHODS OF TREATING PULMONARY DISEASE | BIOGEN IDEC MA INC. (US) | 2003-03-20 | — | — | WO | claimed |
| EP-1429775-A4 | METHODS OF TREATING PULMONARY DISEASE | BIOGEN IDEC INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20040259889-A1 | Methods of treating pulmonary disease | BIOGEN IDEC MA INC. | 2004-12-23 | — | — | US | disclosed |
| EP-1429775-A1 | METHODS OF TREATING PULMONARY DISEASE | Biogen Idec MA Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003022284-A1 | METHODS OF TREATING PULMONARY DISEASE | BIOGEN IDEC MA INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-0497258-B1 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-0467248-B1 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5338743-A | Pancreatitis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-16 | — | — | US | disclosed |
| US-5204346-A | Cognition activators; analgesics; antidepressants; vasodilation; cardiovascular and urogential disorders; | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-20 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| EP-0467248-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259889-A1 | Methods of treating pulmonary disease | ADORA1, ADORA2A, TBXA2R | ADORA1 1/4885IGF1R 3515/4885MAPK1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.